BRIO: Revenues of company up 167%, to Rs 69.91 cr vs Rs 26.09 cr last year. Profits lower 4.3% sequentially to Rs 9.29 cr. Shares up 19.99% to Rs 565 on BSE.

Bharat Parenterals shares surge on Q1 results

Bharat Parenterals consolidated net profit rises 113.76% in the March 2022 quarter

Bharat Parenterals consolidated net profit rises 23.26% in the September 2021 quarter

Bharat Parenterals standalone net profit rises 24.34% in the September 2021 quarter

Bharat Parenterals consolidated net profit rises 16.42% in the June 2021 quarter

Bharat Parenterals consolidated net profit declines 73.49% in the March 2021 quarter

The product patent has been already filed under fast track approval, said Bharat Parenterals.

Bharat Parenterals stock freezes at 5% upper circuit after receiving a license to manufacture Favipiravir

Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.The company has received licence and authorisation from DCGI to manufacture and market fav…

COVID-19: Bharat Parenterals gets DCGI nod for favipiravir oral suspension

​​The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.

Bharat Parenterals gets DCGI nod for favipiravir oral suspension

Bharat Parenterals consolidated net profit declines 32.96% in the December 2020 quarter

The Financial News section features stock market news in addition to stories about bonds, forex, commodities and economic releases.

BRIEF-Bharat Parenterals To Sell Stake In Varenyam Healthcare Private Limited - Investing.com India

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Bharat Parenterals Limited is a pharmaceutical company that makes pharmaceutical formulations. Its products include general, beta-lactam, cephalosporins, antiretroviral, and veterinary.